Berenberg cuts Amrize stock rating on roofing division concerns

Berenberg downgraded Amrize (NYSE:AMRZ) to Hold from Buy, lowering its price target to $46.00. The firm cited concerns over the roofing division's volume and margin pressures, reducing EPS forecasts for 2027-28. Amrize's Q3 2026 earnings beat estimates but revenue missed expectations, with management noting weather and inflation impacts.

Original reporting
Published Nov 9, 2026, 7:20 AM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Nov 9, 2026, 7:29 AM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
AlphAI market briefFinancial news
Primary signal
$AMRZ
Bearish
high confidence
Mentioned
$AMRZ
Relevance
6/10
AlphAI data visualization · based on investing.com
Decision brief

The 30-second read

$AMRZBearishMed
01

Why it matters

The analyst downgrade adds a fresh negative catalyst that could accelerate the stock's decline beyond the earnings reaction.

02

Market read

The downgrade provides a new, actionable signal for traders; the stock may see further downside in the near term.

03

What to watch

Management's share‑buyback program and potential EBITDA growth in 2027 could offset short‑term concerns.

Relevance 6/10Novelty 6/10Timing: pre‑market today

Background

Amrize reported Q3 2026 earnings that slightly beat profit forecasts but missed revenue expectations, with ongoing volume and margin pressure in its roofing division.

Company-level read

Ticker impact

$AMRZBearishHigh confidence
Context

Berenberg downgraded Amrize to Hold and cut the price target to $46, citing concerns about the roofing division.

Expected impact

likely pressure as the market prices in the rating cut and reduced EPS forecasts

Evidence & confidence

The downgrade is a fresh, material change to analyst coverage with a concrete new target, which typically moves the stock immediately.

Market effects

The downgrade highlights weakness in the building‑envelope segment, potentially prompting scrutiny of peers in the roofing and construction materials space.

US‑listed construction‑materials stocks may see modest downside as analysts reassess sector exposure.

Limited to investors tracking US construction‑materials equities; no broader macro impact.

Counterpoint

Some investors may view the lower target as an opportunity if they believe the roofing division's challenges are temporary.

Key entities

  • Berenberg

    Equity research firm that issued the downgrade.

  • Amrize Ltd

    US‑listed building‑envelope and roofing products manufacturer.

Related articles

$AMRZHigh

Jefferies downgrades Amrize stock rating on margin concerns

Jefferies downgraded Amrize (NYSE:AMRZ) to Underperform, cutting its price target to $35.20 from $42.80. Analyst Glynis Johnson cited margin concerns due to rising costs and tough comparisons in 2027. The stock is down 23% year-to-date. Jefferies forecasts continued cost pressures will impact margins. Amrize reported Q3 2026 earnings beating profit estimates but missing revenue targets.

$BETAMed

5 Stocks Analysts Just Downgraded

Wall Street analysts downgraded five stocks: BETA Technologies (BETA), TransUnion (TRU), Molson Coors (TAP), Amrize (AMRZ), and another. Downgrades cited delivery delays, slower growth, soft demand, and cost pressures. BETA's Q3 revenue doubled, but deliveries were delayed. TransUnion's revenue rose 12.2%, but margins slipped. Molson Coors saw net sales fall 1.6% and lowered earnings guidance. Amrize adjusted EBITDA and revenue forecasts due to cost inflation.

Med

Amrize Q3 2026 slides: pricing drives margins amid volume headwinds

Amrize reported Q3 2026 revenues of $3.77B, up 2.2% YoY, with net income rising 3.3% to $558M. Pricing initiatives and acquisitions offset volume declines due to weather. Building Materials segment grew 1.8%, while Building Envelope faced challenges. Guidance updated to $12.2B-$12.4B in revenue and $2.95B-$3.05B in adjusted EBITDA for 2026.

$AMRZMed

DA Davidson raises Amrize stock price target to $43 on mixed Q3

DA Davidson raised its price target for Amrize (NYSE:AMRZ) to $43, citing mixed Q3 results with strong Building Materials offset by Building Envelope pressure. The stock is up 5.5% weekly but down 22% in six months. Amrize guided below consensus but beat EPS estimates by 2.06% while missing revenue by 0.95%. DA Davidson maintains a Neutral rating, awaiting more execution visibility.

$AMRZHighAI 9/10

What Amrize (AMRZ) Said on Its Q3 Earnings Call

Amrize (AMRZ) reported Q3 revenue growth of 1.8% to $2.8B in Building Materials and 3.6% to $929M in Building Envelope. Adjusted EBITDA rose 2.7% in Building Materials but fell 14.6% in Building Envelope due to higher costs. The company expects price-over-cost positivity in Building Envelope by 2027. Amrize reaffirmed its 2026 outlook, targeting $12.2B-$12.4B in revenue and $2.95B-$3.05B in EBITDA. It returned $1.1B to shareholders through dividends and repurchases.

$AMRZMed

Amrize Ltd (AMRZ) Q3 2026 Earnings Call Highlights: Pricing Power Drives Growth

Amrize Ltd (AMRZ) reported Q3 2026 earnings, with revenue and EBITDA guidance updated to $12.2-$12.4B and $2.95-$3.05B. Cement volumes fell 4.2% YoY due to weather, while building envelope EBITDA declined 14.6% from inflation. Price-cost positivity in building envelope delayed to 2027. CEO Jan Jenisch expects 2027 growth but cites inflation and interest rate uncertainties. Free cash flow conversion below 50% target due to higher CapEx.